Lupin Limited (BOM:500257)
India · Delayed Price · Currency is INR 2,112.00
+31.00 (1.49%)
At close: Dec 31, 2025
Lupin Employees
Lupin had 24,006 employees as of March 31, 2025. The number of employees increased by 2,138 or 9.78% compared to the previous year.
Employees
24,006
Change (1Y)
2,138
Growth (1Y)
9.78%
Revenue / Employee
10.31M INR
Profits / Employee
1.80M INR
Market Cap
960.78B
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Mar 31, 2025 | 24,006 | 2,138 | 9.78% |
| Mar 31, 2024 | 21,868 | 935 | 4.47% |
| Mar 31, 2023 | 20,933 | 1,144 | 5.78% |
| Mar 31, 2022 | 19,789 | 1,216 | 6.55% |
| Mar 31, 2021 | 18,573 | 271 | 1.48% |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Tata Consultancy Services | 607,979 |
| Reliance Industries | 403,303 |
| Infosys | 323,578 |
| State Bank of India | 236,226 |
| HDFC Bank | 214,521 |
| ICICI Bank | 182,665 |
| Life Insurance Corporation of India | 91,606 |
| Bajaj Finance | 64,092 |
Lupin News
- 14 days ago - Lupin signs exclusive licensing agreement with Neopharmed for Plasil in Philippines and Brazil - Business Upturn
- 16 days ago - Lupin receives positive CHMP opinion for biosimilar ranibizumab Ranluspec in Europe - Business Upturn
- 16 days ago - Lupin receives US FDA EIR with VAI classification for Nagpur injectable facility - Business Upturn
- 17 days ago - Lupin gets SBTi Validation for emission reduction targets across all emission scopes - Business Upturn
- 21 days ago - Lupin subsidiary forms long-term strategic alliance with PolyPeptide Group to strengthen global peptide supply chain - Business Upturn
- 4 weeks ago - Lupin receives U.S. FDA tentative approval for generic Siponimod tablets - Business Upturn
- 4 weeks ago - Lupin signs exclusive licensing agreement with Valorum Biologics for biosimilar Armlupeg in the US - Business Upturn
- 4 weeks ago - Lupin gets U.S. FDA Approval for Biosimilar Armlupeg - Business Upturn